Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 4/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40665 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18871260 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28817 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL29754 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810706 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2903546 | 1.00 | PYGM (0.57) | PYGMCDK1SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL5091966 | 0.90 | TK2 (0.47) | PYGMCDK1TK2TYMP | |
| SCHEMBL20830476 | 0.90 | PYGM (0.45) | PYGMCDK1TK2P2RY2 | |
| SCHEMBL12642176 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP | |
| SCHEMBL22460365 | 0.89 | CDA (0.48) | PYGMCDK1TK2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885CDK1 4015/4885SLC28A1 231/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885CDK1 4015/4885SLC28A1 231/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885CDK1 4204/4885SLC28A1 317/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885CDK1 4204/4885SLC28A1 317/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885CDK1 4015/4885SLC28A1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.